Navigation Links
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
Date:9/30/2013

SEATTLE, Sept. 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. As previously reported, Phase 1 clinical results in healthy subjects demonstrated that OMS824 is well tolerated and suggest that it has a better clinical therapeutic index or "safety factor" than other PDE10 inhibitors in development. Omeros plans to begin a Phase 2 clinical trial evaluating OMS824 in patients with Huntington's disease later this year. A Phase 2 clinical trial of the drug is already underway in patients with schizophrenia.

Orphan designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. It qualifies a company for benefits that apply across all stages of drug development, including accelerated approval process, seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and waiver of certain administrative fees.

Huntington's disease is estimated to affect approximately 31,000 U.S. patients annually, and the only FDA‑approved treatment for the disease is tetrabenazine, which is indicated for Huntington's-related movement disorders. OMS824 has the potential to improve the cognitive and psychiatric abnormalities as well as the movement disorders associated with the disease.

"Orphan designation by the FDA will help to acc
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... (PRWEB) April 25, 2015 The impact ... still eliciting the excitement of the public and is ... the months of May and June. From March ... their biannual tradition of "Special Prayers." More than 600 ... attended previous Special Prayers and have reported intense experiences ...
(Date:4/25/2015)... 25, 2015 Parker and Sons projects growth ... has spiked in Arizona alongside the growing economy. As a ... employees for April to help account for the rising need ... in April is something we are enthusiastic about. It means ... Kelly, president at Parker and Sons. , Indeed, Parker and ...
(Date:4/25/2015)... 2015 On Friday, April 17, Interstate ... annual Best Implementation Award. This award is given ... use of RFID technology to improve its manufacturing, supply ... that best demonstrates how RFID is delivering real value ... Journal Live! 2015 in San Diego, the RFID industries ...
(Date:4/24/2015)... April 24, 2015 Constellations Recovery celebrates ... in Westchester County. Just 35 miles from New York ... back into everyday life while recovering from addiction. The ... 2015, will allow therapists, doctors and treatment centers to ... more about the opportunities offered by Constellations Recovery.,  , ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Ryadon is ... wide range of capabilities and services to complement any ... Ryadon's Quantity Discount Program will be offered on all ... , Order 4-19: Receive 10% discount - Order 20+: ... Using the Drawer Slides Products, ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... HealthDay Reporter , WEDNESDAY, June 15 (HealthDay News) -- ... leading nations in terms of life expectancy, and the gap ... Life expectancy in some areas of the United States is ... nations, the report found. "The gap between the U.S. ...
... Reporter , WEDNESDAY, June 15 (HealthDay News) -- Severely ... fade or become less frequent after having weight-reducing gastric ... the three years following surgery, 70 percent of the ... saw their migraines reduced from five to two a ...
... as nave and irrational, can actually help consumers cope ... to a new study in the Journal of ... an individual invokes mystical, supernatural forces to understand, predict, ... write authors Yannik St. James (HEC Montreal), Jay M. ...
... 2011, the New York Academy of Sciences will ... molecular biologists and patient advocates to discuss current ... and management of the cognitive symptoms of MS. ... Dysfunction in Multiple Sclerosis: New Approaches to Diagnosis ...
... -- A person scanning baggage or X-rays stands a ... they aren,t feeling anxious, according to a new laboratory ... a test in which they searched for particular shapes ... searching performed by airport security teams and radiologists. ...
... of asbestos-contaminated dust, have a higher level of genetic somatic ... lower. This has been shown in a new study carried ... the University of Haifa,s Department of Biology in Oranim. "This ... higher levels of asbestos in the environment and the frequency ...
Cached Medicine News:Health News:U.S. Found to Be Losing Ground in Life Expectancy 2Health News:U.S. Found to Be Losing Ground in Life Expectancy 3Health News:For Many, Weight-Loss Surgery Also Eases Migraines 2Health News:For Many, Weight-Loss Surgery Also Eases Migraines 3Health News:Magical thinking helps dieters cope with unrealistic expectations 2Health News:The New York Academy of Sciences to host a symposium on cognitive dysfunction in multiple sclerosis 2Health News:Anxious searchers miss multiple objects 2Health News:Genetic mutation linked to asbestos exposure 2
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: